BACKGROUND:Cancer patients are at increased risk for depression compared with individuals with no cancer diagnosis, yet few interventions target depressed cancer patients. METHODS: Efficacy of psychotherapeutic and pharmacologic interventions for depression in cancer patients who met an entry threshold for depressive symptoms was examined by meta-analysis. Five electronic databases were systematically reviewed to identify randomized controlled trials meeting the selection criteria. Effect sizes were calculated using Hedges' g and were pooled to compare pre- and postrandomization depressive symptoms with a random effects model. Subgroup analyses tested moderators of effect sizes, such as comparison of different intervention modalities, with a mixed effects model. All statistical tests were two-sided. RESULTS: Ten randomized controlled trials (six psychotherapeutic and four pharmacologic studies) met the selection criteria; 1362 participants with mixed cancer types and stages had been randomly assigned to treatment groups. One outlier trial was removed from analyses. The random effects model showed interventions to be superior to control conditions on reducing depressive symptoms postintervention (Hedges' g = 0.43, 95% confidence interval = 0.30 to 0.56, P < .001). In the four psychotherapeutic trials with follow-up assessment, interventions were more effective than control conditions up to 12-18 months after patients were randomly assigned to treatment groups (P < .001). Although each approach was more effective than the control conditions in improving depressive symptoms (P < .001), subgroup analyses showed that cognitive behavioral therapy appeared more effective than problem-solving therapy (P = .01), but not more effective than pharmacologic intervention (P = .07). CONCLUSIONS: Our findings suggest that psychological and pharmacologic approaches can be targeted productively toward cancer patients with elevated depressive symptoms. Research is needed to maximize effectiveness, accessibility, and integration into clinical care of interventions for depressed cancer patients.
RCT Entities:
BACKGROUND:Cancerpatients are at increased risk for depression compared with individuals with no cancer diagnosis, yet few interventions target depressed cancerpatients. METHODS: Efficacy of psychotherapeutic and pharmacologic interventions for depression in cancerpatients who met an entry threshold for depressive symptoms was examined by meta-analysis. Five electronic databases were systematically reviewed to identify randomized controlled trials meeting the selection criteria. Effect sizes were calculated using Hedges' g and were pooled to compare pre- and postrandomization depressive symptoms with a random effects model. Subgroup analyses tested moderators of effect sizes, such as comparison of different intervention modalities, with a mixed effects model. All statistical tests were two-sided. RESULTS: Ten randomized controlled trials (six psychotherapeutic and four pharmacologic studies) met the selection criteria; 1362 participants with mixed cancer types and stages had been randomly assigned to treatment groups. One outlier trial was removed from analyses. The random effects model showed interventions to be superior to control conditions on reducing depressive symptoms postintervention (Hedges' g = 0.43, 95% confidence interval = 0.30 to 0.56, P < .001). In the four psychotherapeutic trials with follow-up assessment, interventions were more effective than control conditions up to 12-18 months after patients were randomly assigned to treatment groups (P < .001). Although each approach was more effective than the control conditions in improving depressive symptoms (P < .001), subgroup analyses showed that cognitive behavioral therapy appeared more effective than problem-solving therapy (P = .01), but not more effective than pharmacologic intervention (P = .07). CONCLUSIONS: Our findings suggest that psychological and pharmacologic approaches can be targeted productively toward cancerpatients with elevated depressive symptoms. Research is needed to maximize effectiveness, accessibility, and integration into clinical care of interventions for depressed cancerpatients.
Authors: Sonia A Duffy; David L Ronis; Marcia Valenstein; Michael T Lambert; Karen E Fowler; Lynn Gregory; Carol Bishop; Larry L Myers; Frederic C Blow; Jeffrey E Terrell Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-11 Impact factor: 4.254
Authors: Josée Savard; Sébastien Simard; Isabelle Giguère; Hans Ivers; Charles M Morin; Elizabeth Maunsell; Pierre Gagnon; Jean Robert; Danièle Marceau Journal: Palliat Support Care Date: 2006-09
Authors: Gary Rodin; Nancy Lloyd; Mark Katz; Esther Green; Jean A Mackay; Rebecca K S Wong Journal: Support Care Cancer Date: 2006-10-21 Impact factor: 3.603
Authors: Susie M Wilkinson; Sharon B Love; Alex M Westcombe; Maureen A Gambles; Caroline C Burgess; Anna Cargill; Teresa Young; E Jane Maher; Amanda J Ramirez Journal: J Clin Oncol Date: 2007-02-10 Impact factor: 44.544
Authors: Arnstein Mykletun; Ottar Bjerkeset; Michael Dewey; Martin Prince; Simon Overland; Robert Stewart Journal: Psychosom Med Date: 2007-04-30 Impact factor: 4.312
Authors: Soon-Hyun Ahn; Hyun Jun Hong; Soon Young Kwon; Kee Hwan Kwon; Jong-Lyel Roh; Junsun Ryu; Jun Hee Park; Seung-Kuk Baek; Guk Haeng Lee; Sei Young Lee; Jin Choon Lee; Man Ki Chung; Young Hoon Joo; Yong Bae Ji; Jeong Hun Hah; Minsu Kwon; Young Min Park; Chang Myeon Song; Sung-Chan Shin; Chang Hwan Ryu; Doh Young Lee; Young Chan Lee; Jae Won Chang; Ha Min Jeong; Jae-Keun Cho; Wonjae Cha; Byung Joon Chun; Ik Joon Choi; Hyo Geun Choi; Kang Dae Lee Journal: Clin Exp Otorhinolaryngol Date: 2017-01-03 Impact factor: 3.372
Authors: Sue V Petzel; Rachel Isaksson Vogel; Julie Cragg; Molly McClellan; Daniel Chan; Julie A Jacko; François Sainfort; Melissa A Geller Journal: J Psychosoc Oncol Date: 2018-05-23
Authors: Catherine E Mosher; Joseph G Winger; Barbara A Given; Safi Shahda; Paul R Helft Journal: Support Care Cancer Date: 2017-04-22 Impact factor: 3.603
Authors: Michael J Fisch; Fengmin Zhao; Judith Manola; Andrew H Miller; William F Pirl; Lynne I Wagner Journal: Psychooncology Date: 2014-06-14 Impact factor: 3.894